Names
CeeNU® CCNU LomustineIndications and usage
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
Side effects needing medical attention
Fever, chills or sore throat; unusual bleeding or bruising; infection; confusion; slurred speech; sores in mouth and on lips; swelling of feet or lower legs; unusual decrease in urination; unusual tiredness or weakness; yellowing of eyes and skin; cough or shortness of breath.